Skip to main content
Premium Trial:

Request an Annual Quote

Holmes Trial Delay Sought

Elizabeth Holmes, the founder and former CEO of Theranos, is seeking to push back the start of her trial, scheduled for July, as she is pregnant and expects to give birth then, the Wall Street Journal reports.

Holmes was indicted in 2018 on charges of wire fraud and conspiracy to commit wire fraud. The Mercury News reported last year that another fraud charge had been added stemming from a patient's testing results. Theranos once claimed to be able to run a range of blood tests using a small amount of blood from a finger prick. But a series of articles in the Journal beginning in 2015 called the company's ability to run those tests in to question and regulators uncovered testing issues at the company, which closed in 2018.

Prosecutors have alleged that Holmes and Ramesh 'Sunny' Balwani, the company's former president, committed fraud as they knew Theranos could not perform the tests as claimed. Holmes and Balwani have pleaded not guilty.

According to CNBC, her lawyers are seeking to push the start of her trial back to the end of August 2021. Her trial was previously postponed due to the COVID-19 pandemic.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.